Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.82 |
| ▸ | PAM | P19021 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784181 | 0.93 | ALDH1A1 (0.96) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL361779 | 0.91 | ALDH1A1 (1.00) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL28250075 | 0.89 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL57331 | 0.87 | ALDH1A1 (0.85) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL31245908 | 0.87 | ALDH1A1 (0.85) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL27499661 | 0.87 | ALDH1A1 (0.92) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL6160393 | 0.84 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL224663 | 0.84 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL18430348 | 0.84 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL22211316 | 0.84 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2022-01-04 | — | — | US | disclosed |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | KANONCURE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3366687-B1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NAT UNIV CORP TOTTORI UNIV (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2019-02-21 | — | — | US | disclosed |
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-0632036-B1 | Amide derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO CO (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | ALDH1A1 378/4885MAPK1 522/4885L3MBTL1 4871/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | ALDH1A1 378/4885MAPK1 522/4885L3MBTL1 4871/4885 |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | ALDH1A1 3161/4885MAPK1 4293/4885L3MBTL1 2866/4885 |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | HDGF, SHC1, HGF | ALDH1A1 914/4885MAPK1 216/4885L3MBTL1 2323/4885 |
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | MMP1, SERPINB1, LGALS1 | ALDH1A1 130/4885MAPK1 390/4885L3MBTL1 2085/4885 |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | MMP1, SERPINB1, LGALS1 | ALDH1A1 130/4885MAPK1 390/4885L3MBTL1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.